Biorisk: Doomsday Bug, Resistant to Every Drug, Found in
Biorisk: Doomsday Bug, Resistant to Every Drug, Found in L.A.
1 Feb 2017
Los Angeles County Health authorities issued a national biorisk warning on Tuesday after identifying a patient infected with the 100 percent drug-resistant “mcr-1” bacterial pathogen, apparently acquired through international travel.
X-ray crystal structure of the catalytic domain of the MCR-1 protein.
Scientists first reported the emergence of the plasmid-encoded mcr-1 gene, which is completely resistant to all known drugs in a Pennsylvania female patient with a urinary tract infection in November 2015. The discovery set off a worldwide biorisk warning from the World Health Organization, causing bacteriologists to scour their international “collections” of thousands of frozen bacterial isolates in search of any similar gene DNA.
The British Lancet medical journal reported last May that English and Chinese microbiologists had found almost 100 instances of the biorisk gene. With some of the frozen samples going back over five years, researchers indicated that mcr-1 resistance may be more widely distributed than expected.
The L.A. County biorisk warning is the first public disclosure that the mcr-1 gene “has been reported in human specimens from five additional states and in animal specimens from two states.”
California hospital-based health providers are being directed to follow LAC Department of Public Health recommendations regarding infection control, testing, and reporting for patients with suspected and confirmed mcr-1 organisms. All LAC health care facilities also must report any mcr-1 indications within 24 hours of discovery.
The mcr-1 gene is zoonotic, which means it can be transferred from humans to animals or vice versa. After it was first determined in June that seagulls may carry mcr-1, health officials realized that the gene could be subject to airborne transmission; transmission through animal interactions; through handling infected meat; and by drinking animal-contaminated water.
National Geographic reported that mcr-1 drug-resistance is due to mobile genetic elements called plasmids. But rather than just the risk of infection spreading from one person or one animal to another, “plasmids sequencing and subcloning” can move from one bacterial species to another. That has already been documented with E. coli and Klebsiella bacteria in the human stomach swapping their plasmids. That means no one is sure how far and how fast mcr-1 drug resistance will, or has already, spread.
Antibiotic Resistance Gene mcr-1
Not Easily Spread
2
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...
Continue Reading
Helping Veterans: A Call That Never Fades If there's one thing that never changes, it's the enduring need to support those who have served. Semper Fi & America's Fund has been at the forefront of this mission for over a decade, and their annual Double Down for Veterans Match Campaign is nothing short of a testament to unwavering commitment. Kicking off for the 15th time,...
Continue Reading
Riding the Waves of Real Estate Pricing Homeowners dipping their toes into the real estate market know that setting the right price ain't a walk in the park. Luckily, Matt Nuzie, Shelton's real estate pro, has peeled back the layers on comparative market analyses (CMA) in a HelloNation piece. This isn't just about tossing a number out there—it's about understanding the...
Continue Reading
Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...
Continue Reading
Gildan's Legal Storm: Fraud Allegations When news hits about a big player like Gildan Activewear (NYSE: GIL) facing a class-action lawsuit, it's like a thunderstorm for investors who traded their stocks between February 19, 2025, and June 15, 2026. This lawsuit alleges what we some might call classic financial engineering—channel stuffing to be precise—that’s got...
Continue Reading
Small Component, Big Impact: The Anode Rod Picture this: You’ve got a trusty water heater keeping your showers steamy, but lurking inside is a villain called rust. Enter the unsung hero—the anode rod. It might not be glamorous, but this little piece of metal works overtime to save your tank from a watery grave. Tim Fessler and Dave Super, seasoned plumbing hotshots...
Continue Reading
Building Bridges Across Waters These aren't the afternoons of trading stocks, folks—this one dives into the depths of the ocean and the tumultuous waters between China and Malaysia. October 30 saw the China-Malaysia Youth Ocean Dialogue take place at the China Media Group Sanya Studio, bringing together some sharp minds from both nations, tackling something that goes...
Continue Reading
What's the Deal With Those Ancient Quotes? There's nothing like a quote from the Warring States Period to set the stage for good ol' fashioned governance chatter. Lu Buwei's words about rulers and compass points is historic, sure, but it speaks to the core need for standards in today's China. This isn't just some fortune cookie wisdom; it's a clarion call for order and...
Continue Reading
When the Rubber Hits the Road: Coverage Gaps Ever been in a fender bender and found out the other driver’s insurance barely covers a dent, let alone a serious crash? Believe me, it's no picnic. Chuck Clark from HelloNation digs into this with a deep dive on underinsured motorist coverage, or UIM for short. It's an eye-opener—especially if you're assuming your auto...
Continue Reading
Rethinking AI with Sovereignty in Mind A bouquet of tech buzzwords lands on every investor's doorstep with the unveiling of Context Labs' latest contraption. We’re talking about the AI Distillery™, which promises enterprises a way to run sovereign AI systems by keeping data in-house. Now, if you’re nodding along to the buzz, let's cut through the clutter....
Continue Reading
Top 5 Most Recently Viewed Articles
Logan Ridge Finance Corporation Announces Q1 2025 Earnings Release Logan Ridge Finance Corporation (NASDAQ: LRFC) has scheduled to share its financial results for the first quarter soon, wrapping up on March 31, 2025. The eagerly awaited earnings release will occur on a Thursday, with a conference call slated for a Friday morning where investors and stakeholders can gain...
Continue Reading
Maxus Mining Uncovering High-Grade Mineralization at Alturas East Maxus Mining Inc. (CSE: MAXM | FRA: R7V) recently published highlights from its 2025 exploration program at the Alturas Project, which is situated in British Columbia's Slocan Mining Division. The Alturas East Block, a key focus area, spans over 1,094 hectares known for containing rich mineral resources and...
Continue Reading
Growing Interest in Lightweight Pre-Insulated Pipes The global market for pre-insulated pipes was valued at USD 6.1 billion in 2023 and is expected to grow significantly, with projections indicating it could reach USD 11.2 billion by 2034. This growth reflects a compound annual growth rate (CAGR) of 5.7%, with an anticipated year-on-year increase of 6.3% in the near...
Continue Reading
Market Surge for Korro Bio and Its Implications In a remarkable display of market confidence, Korro Bio's stock has soared to a 52-week high, reaching an impressive price level of $98.0 USD. This significant milestone reflects a period of notable growth for the company, having achieved an astonishing 433.96% increase over the past year. Investors have enthusiastically...
Continue Reading
Merck's New Challenge in Colorectal Cancer Treatment In a key development in medical science, Merck has revealed that its newest therapy designed for a specific type of colorectal cancer fell short of its main goals during a late-stage trial. This news is significant not just for patients but also for healthcare professionals, as the quest for effective treatments...
Continue Reading